Engineered Antibodies

Engineered antibodies are a large and rapidly expanding market. There are a growing number of antibody-based therapies that have been approved by the FDA for the treatment of cancer, including Rituxan, Herceptin, Campath, Erbitux, Avastin and Vectibix. Monoclonal antibodies (mAbs) are now part of conventional therapy used by oncologists.

Seattle Genetics is developing multiple therapeutic monoclonal antibodies that target highly expressed tumor antigens found on many carcinomas and hematologic malignancies. When engineered in chimeric, humanized or in fully human form, antibodies can be rendered non-immunogenic allowing for multiple cycles and long-term use in treating cancer patients. This class of antitumor agent has low systemic toxicity and can be efficacious in regressing tumors.

Engineered Antibody Product Candidates

Seattle Genetics' three lead engineered antibody product candidates are dacetuzumab (SGN-40), lintuzumab (SGN-33) and SGN-70. These humanized antibodies target various hematologic malignancies including non-Hodgkin lymphoma, multiple myeloma, acute myeloid leukemia and Hodgkin lymphoma, as well as autoimmune disease.